Market Overview - The A-share pharmaceutical and biotechnology index increased by 0.50% last week, underperforming the CSI 300 index by 0.58 percentage points and the ChiNext index by 1.82 percentage points, ranking 25th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index fell by 6.07%, underperforming the Hang Seng Index by 4.96 percentage points [4] R&D Progress - Last week, several clinical applications were newly undertaken, including CMS-D008 injection by Kangzhe Pharmaceutical and KC1036 tablets by Kangchen Pharmaceutical [4] - Other IND applications included HSK46575 tablets by Haishi Pharmaceutical, injection of Lankangyilong monoclonal antibody by Bailitianheng, and injection of BL-M11D1 [4] - Notable ongoing clinical trials include ICP-538 by Nocera Biopharma and DC6001 by China Resources Sanjiu in Phase I, HLX43 by Fuhong Hanlin and Punanli monoclonal antibody by Tianjing Biopharma in Phase II, and SYH2053 and SYS6010 by Shiyao Group in Phase III [4] Investment Outlook - The company maintains a positive outlook on the pharmaceutical sector's recovery, reiterating the investment thesis based on the three stages of clinical value: 1. "0→1" technological breakthroughs in innovative drugs, particularly in oncology, weight loss, and autoimmune diseases, as well as advancements in innovative medical devices like brain-machine interfaces [5] 2. "1→10" clinical validation with high-quality domestic innovative drugs accelerating overseas authorization and the rise of high-end medical devices [5] 3. "10→100" efficiency in China, where CXO companies leverage low costs and high efficiency to build competitive advantages, particularly in the disposable medical supplies sector [5] - The focus is on the accelerated overseas expansion of innovative drugs and their upstream CXO, as well as the innovation and upgrade of high-end medical devices and high-value consumables [5]

未来已来——2025 年脑机接口前沿热点研究进展 20260227 摘要 实时脑语音神经假体通过解码语音运动皮层神经信号，实现闭环音频反 馈的即时语音合成，显著降低延迟，恢复自然表达。针对渐冻症患者的 实验表明，合成语音与目标语音相关性 R2 达 0.83，人类听众识别准确 性达 100%，并支持个性化语音克隆。 AI 辅助的非侵入式脑机接口采用"共享自主权"框架，结合 CNN 与卡 尔曼滤波器，提升控制精度与效率。在光标控制任务中，截瘫患者目标 命中率提升接近 4 倍，健康参与者提升 2.1 倍。AI 辅助使截瘫患者能够 完成随机放置积木顺序的任务。 跨日简单想象动作表征研究发现，跨日信号漂移被约束在固定的原表征 空间内，核心编码逻辑稳定。患者仅需 8 分钟校准即可恢复既有性能， 系统稳定工作时长提升到最长 7 个月，显著提升神经假肢的临床可用性。 "读取内心独白"研究表明，尝试发声、内心语言与发声均可在运动皮层 表征，且相关脑区相近。在 6 区对 7 种语言行为进行词汇解码时，解码 准确性显著高于随机水平，提示内心语言在可解码性上具备较高潜力。 Q&A 本次专题研究选取了哪些前沿方向与代表性成果，整体产业 ...

Group 1: Macro and Strategy Insights - The macro view for March indicates a gradual improvement in risk appetite, influenced by external factors such as the Iran conflict and expectations surrounding the US-China summit, which may lead to a more neutral market impact [7] - The strategy perspective suggests that the market lacks a clear main line, with a tendency for continued oscillation, recommending a flexible approach while waiting for trend opportunities [8] - The quantitative view highlights the absence of a main line in March, with market capitalization expected to decline further, presenting a potential opportunity for positioning [9] Group 2: March Gold Stock Portfolio - The selected gold stock portfolio for March includes: - Electronics: Shiyun Circuit - Consumer Electronics: Hongrida - Communication: Kexin Innovation Source - Media: Perfect World - Light Industry: Yingke Regeneration - Chemicals: Xinfengming - Coal: Hengyuan Coal Power - Non-ferrous: Salt Lake Co. - Machinery: Zoomlion - Agriculture: Youran Animal Husbandry [11] - The rationale for Shiyun Circuit is its deep ties with Tesla and potential benefits from emerging fields such as commercial aerospace and intelligent driving, which could lead to significant growth opportunities [11] - Hongrida is transitioning its focus towards AI chip cooling and optical communication, with expectations for substantial production scale in 2026, driven by recent advancements in 3D printing technology [14][15] - Kexin Innovation Source is positioned to capitalize on the growing demand for AI liquid cooling solutions, with anticipated breakthroughs in both domestic and international markets [18][19] - Perfect World is expected to see revenue growth from its game "Yihuan," with projections indicating potential earnings exceeding market expectations [22][24] - Yingke Regeneration is forecasted to experience accelerated revenue growth due to the rising demand for easy-install plastic wall panels and the operational efficiency of its Vietnamese base [26][29] - Xinfengming is anticipated to benefit from a recovery in polyester filament profitability, supported by a slowdown in industry capacity expansion [32] - Hengyuan Coal Power is viewed as a premium coking coal asset, with expected price increases driven by global supply constraints [36][39] - Salt Lake Co. is expected to benefit from rising lithium prices and strong demand for potassium fertilizers, enhancing its market valuation [43][44] - Zoomlion is positioned for growth through its diversified machinery offerings and global expansion strategies, with a focus on non-excavation machinery [48][50] - Youran Animal Husbandry is set to benefit from a cyclical recovery in raw milk prices and beef cattle, with significant growth potential in both its raw milk and cattle businesses [55][56]

Core Viewpoint - The integration of embodied intelligence and brain-machine interfaces is entering a historic strategic window, driven by supportive policies and significant collaborations in the industry [1]. Policy and Industry Context - In January 2026, a joint policy by eight departments, including the Ministry of Industry and Information Technology, was released to accelerate the industrialization and commercialization of brain-machine interfaces and embodied intelligence products [1]. - The policy emphasizes innovation in embodied intelligence products and the establishment of humanoid robot pilot bases to facilitate the transition from laboratory to production line [1]. - In February 2026, the Ministry further highlighted brain-machine interfaces and embodied intelligence as key disruptive technologies alongside 6G and quantum technology, signaling a national push for breakthroughs [1]. Company Collaboration - On February 28, 2026, Strong Brain Technology signed a strategic cooperation agreement with the Hong Kong University Shanghai Intelligent Computing Research Institute, marking a new phase in their collaboration in the field of brain-machine interface and embodied intelligence [1][3]. - The signing ceremony was attended by key figures from both organizations, indicating a strong commitment to this partnership [3]. Technological Innovations - Strong Brain Technology focuses on non-invasive brain-machine interfaces and human-machine integration, with proprietary technologies in neural signal acquisition and thought control [5]. - The company has developed a dexterous hand, Revo 2, weighing 383 grams with a load capacity of 20 kilograms and a precision of 0.1mm, achieving a grip-to-weight ratio of 52:1, setting a new industry standard [5]. - The company emphasizes the importance of stability and precision in embodied intelligence, highlighting the iterative process of learning from failures to enhance system performance [6]. Research and Development Focus - Strong Brain Technology and the Hong Kong University will collaborate on three main research areas: platform co-development, multimodal data integration, and task evaluation systems [6]. - The goal is to create a humanoid robot experimental platform that adapts to high degrees of freedom dexterous hands and to establish a comprehensive data loop covering brain signals, visual information, and tactile feedback [6]. Future Outlook - The partnership aims to leverage the strengths of both organizations to facilitate the transition from fundamental research to industrial applications, particularly in smart manufacturing and medical rehabilitation [13]. - Strong Brain Technology anticipates that the collaborative efforts will enable the widespread application of "brain-eye-hand" technologies, benefiting various sectors [13].

Core Viewpoint - The report highlights the strong growth potential of the Chinese pharmaceutical industry, particularly in innovative drugs, with a significant increase in the number of therapies under development and a growing share in the global market [10]. Market Overview - The CITIC pharmaceutical index rose by 0.41% this week, underperforming the CSI 300 index by 0.67 percentage points, ranking 24th among 30 primary industries [9]. - The top ten stocks by growth this week included Aidi Te, Koyuan Pharmaceutical, and Duorui Pharmaceutical, while the bottom ten included Zexing Pharmaceutical and Meihua Medical [9]. Investment Themes - **Innovative Drugs**: China has become a key player in global innovative drug development, with the total overseas licensing amount for domestic new drugs exceeding $10 billion for the first time in 2021, indicating a sustained increase in overseas licensing activity [10]. - **Traditional Chinese Medicine**: The market for essential medicines is expected to see significant growth, particularly for unique essential medicines, as the new medical insurance catalog expands [12]. - **Medical Devices**: The pressure from centralized procurement for high-value consumables is easing, and the industry is expected to see continued development driven by innovation [13]. - **Pharmaceutical Supply Chain (CXO + APIs)**: The domestic CXO companies are experiencing good growth in front-end orders, which is expected to translate into performance improvements [13]. - **Life Sciences Services**: The industry is seeing a recovery in demand, with a positive outlook for revenue growth starting from Q4 2024 [13]. Company Performance and Projections - **Medpace**: The company reported a revenue growth of 20% and has a clear revenue and profit growth guidance for 2026, with expected revenue growth of 4.7-6.0% [15][88]. - **IQVIA**: The company is benefiting from an improved macro environment, with a projected total revenue of $171.5-173.5 billion for 2026 [55]. - **Lonza**: The company expects a revenue growth of 11-12% for 2026, driven by strong demand for outsourcing and maturing growth projects [34][38]. - **Samsung Biologics**: The company anticipates a revenue growth of 15-20% for 2026, with strong performance in its biologics segment [34][46]. Financial Highlights - **IQVIA**: Reported Q4 2025 revenue of $4.364 billion, a year-on-year increase of 10.3% [53]. - **Labcorp**: Achieved Q4 2025 revenue of $3.52 billion, a year-on-year increase of 5.7% [79]. - **Medpace**: Reported Q4 2025 revenue of $709 million, a year-on-year increase of 32.1% [88].

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 months [15]. Core Insights - Tsinghua University's research team has developed a new brain-computer interface (BCI) solution using a lantern-shaped flexible electrode that addresses the long-term recording stability issues of invasive BCIs. This innovation allows for stable signal recording over months with minimal immune response, unlike traditional cortical electrodes [4][5]. - The new electrode design shows superior decoding capabilities, achieving a prediction accuracy of nearly 98% in animal experiments related to memory-guided decision-making, significantly outperforming traditional cortical electrodes. This research opens new pathways for obtaining deep cognitive-related information and provides a new reference for BCI design [5]. - The global BCI market is projected to grow rapidly, with an estimated market size of approximately $2.62 billion in 2024, reaching $2.94 billion in 2025, and potentially growing to $12.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 17.35% over the next decade. In China, the BCI market is expected to grow from 3.2 billion yuan in 2024 to 6.14 billion yuan by 2028 [6]. Summary by Sections Investment Highlights - The innovative electrode design from Tsinghua University addresses the core issue of long-term stable recording in invasive BCIs, with animal tests showing stable signal recording for months [4]. - The new BCI technology has the potential to enhance the understanding of cognitive processes and decision-making through improved data acquisition from neural regions [5]. Market Outlook - The BCI market is positioned as a key growth area, with significant projections for expansion in both global and Chinese markets, supported by government initiatives to promote high-tech industries [6]. - Companies to watch in this sector include Yanshan Technology, Hanwei Technology, Sanbo Brain Science, and others, indicating a robust investment landscape [6].

Group 1 - The National Market Supervision Administration (NMSA) announced the release of 4,929 national standards in 2025, representing a 56% year-on-year increase, indicating significant progress in the construction of the national standard system [1] - NMSA is focusing on emerging industries such as new energy vehicles, lithium batteries, and photovoltaics, implementing a standard enhancement action with 167 key technical standards under development [1] - In the field of artificial intelligence, NMSA has initiated a special action for 100 standards, with 15 national standards already published [1] Group 2 - NMSA has updated and upgraded over 1,800 national standards in traditional industries, including petrochemicals, building materials, and textiles, focusing on ten key industries [1] - The NMSA has made 32,000 national standards publicly available for free, achieving over 100 million views and 24 million downloads in a year, with significant interest in standards related to smart cities and safety [2] - NMSA plans to accelerate standardization reform, streamline standard levels, and enhance standards in key areas to build a unified and efficient national standard system [2]

Core Insights - The National Bureau of Statistics released the "2025 National Economic and Social Development Statistical Bulletin" highlighting significant advancements in China's aerospace and technology sectors [1] Aerospace Industry - A total of 92 space launches were completed in 2025, with 50 of these being commercial space launches [1] - The successful launch of the Tianwen-2 mission marks a significant milestone in asteroid sampling and return missions [1] - Breakthroughs in reusable rocket technology were noted, with the successful maiden flights of Zhuque-3 and Long March 12甲 achieving successful orbit insertion [1] Defense and Military Technology - The first domestically designed and built electromagnetic aircraft carrier, "Fujian," has been commissioned into service [1] Quantum Computing and Energy - The superconducting quantum computing prototype "Zuchongzhi-3" has been successfully constructed, indicating progress in quantum technology [1] - The "artificial sun" project achieved a world record of "one hundred million degrees for a thousand seconds," showcasing advancements in nuclear fusion technology [1] Scientific Research and Development - The Jiangmen neutrino experiment large scientific facility has officially commenced operations, contributing to fundamental physics research [1] - The domestically developed deep learning AI model, DeepSeek, has garnered global attention for its capabilities [1] - The first clinical trial of an invasive brain-computer interface has been successfully conducted, marking a significant step in neurotechnology [1] - The domestically produced low-temperature high-current ion implanter has demonstrated industrialization capabilities [1]

事件：2月27日，华尔街日报显示，马斯克、阿尔特曼和中国角逐脑机接口领域，瞄准3，200亿美元潜在市场，预 计中国将在定于3月公布的下一个五年计划中重点提及BCI技术。 事件：2月27日，华尔街日报显示，马斯克、阿尔特曼和中国角逐脑机接口领域，瞄准3，200亿美元潜在市场，预 计中国将在定于3月公布的下一个五年计划中重点提及BCI技术。 【南京熊猫电子】聚焦非侵入式多模态交互，覆盖医疗、工业、军工，脑控外骨骼临床试用，2026 年冲刺三类 证。 【创新医疗】参股博灵脑机，推进植入式 BCI 外骨骼临床试验，2026 上半年申报注册，剑指国内首款获批。 【南京熊猫电子】聚焦非侵入式多模态交互，覆盖医疗、工业、军工，脑控外骨骼临床试用，2026 年冲刺三类 证。 WSJ预计中将在定于3月公布的下一个五年计划中重点提及BCI（侵入式脑机）技术。 WSJ预计中将在定于3月公布的下一个五年计划中重点提及BCI（侵入式脑机）技术。 ...

Core Viewpoint - The company, established in 2005, is a leading manufacturer of smart electric beds, with an annual production capacity of one million units, and has built strong partnerships with major clients, positioning itself for continued growth in the smart bed market [1][2]. Group 1: Company Overview - The company has developed a stable customer base both domestically and internationally, forming long-term strategic partnerships with notable clients such as SSB and TSI [1]. - By December 2025, the company will be recognized as a senior member of the World Internet Conference, sharing its advancements in smart sleep technology with global partners [1]. - The company aims to maintain its industry leadership through technological advantages, global market strategies, and a "hardware + service" ecosystem [1]. Group 2: Market Growth and Strategy - The smart electric bed industry is entering a growth phase, driven by technological empowerment, policy support, and rising health demands, with the global market projected to grow from $3.19 billion in 2024 to $4.62 billion by 2029, at a CAGR of 8.9% [2]. - The company is enhancing product intelligence, transitioning from passive monitoring to active health management [2]. - In the domestic market, the company is expanding through brand integration and marketing strategies, while in international markets, it is leveraging supply chain capabilities to diversify its presence [2]. Group 3: Future Industry Focus - The company is aligning with the national "14th Five-Year Plan," focusing on brain-computer interfaces and robotics as key future industries [3]. - It has established a digital sleep fund to incubate innovative sleep solutions, with a focus on non-invasive brain-computer interface technology [4]. - The company has developed a new generation of brain-computer interface products, achieving high accuracy in sleep monitoring and addressing industry pain points [4]. Group 4: Financial Projections - The company is expected to achieve revenues of 3.038 billion yuan, 3.252 billion yuan, and 3.602 billion yuan from 2025 to 2027, with net profits of 196 million yuan, 242 million yuan, and 299 million yuan respectively [6]. - The current stock price corresponds to a P/E ratio of 33.2X, 27.0X, and 21.8X for the respective years [6].